Evonik's Order Books Look Full, but Restructuring Still Eats Into the Bottom Line

Evonik's finance chief is painting a brighter picture for the start of 2027, pointing to healthy demand at the close of this year and well-stocked order books. Michael Rauch's remarks, reported by Reuters, stop short of a hard target for the coming year — and they land alongside a reminder that the group's overhaul is still generating substantial charges.

A stronger fourth quarter, and a firmer first quarter to follow

Despite seasonally lower volumes, Evonik expects fourth-quarter 2026 earnings above the prior-year level. According to Chemweek, Rauch sees the first quarter of 2027 coming in clearly ahead of the same period a year earlier. For investors, that outlook is less a backward glance than a test of whether the recovery carries past the turn of the year. Full order books support the case; they are no substitute for a quantified forecast for the next financial year.

On the operating side, Evonik's third quarter already showed momentum. Adjusted EBITDA reached €629 million, up 40% year on year, on revenue that rose 13% to €3.83 billion. Higher selling prices and larger volumes both contributed, so the gain does not rest on pricing alone. One caveat: the figure fell just shy of the €633.2 million analyst consensus. Growth against the prior year and a positive earnings surprise are two different things.

The bottom line tells a different story

Adjusted EBITDA and net profit diverge sharply. Evonik remained in the red, posting a net loss of €53 million, an improvement on the prior-year quarter's €106 million. The group also set aside €313 million for additional ETM measures. The loss narrowed, but a return to profitability is not yet on the table — anyone assessing the recovery should not confuse the adjusted metric with the result after all charges.

A chunk of that gap comes from the cost-cutting programme, which has been extended through 2029 and will eliminate 3,200 jobs worldwide. For the fourth quarter of 2026, Evonik anticipates an additional burden in the high double-digit millions from restructuring provisions, Reuters reported. Those charges dilute the benefit of better trading for reported earnings — the overhaul is both a drag and part of the effort to lift future earning power.

A helping hand from competitors' troubles

Part of the operating tailwind comes from outside the company. Reuters reports supply disruptions at Asian competitors stemming from the Middle East crisis, a development that has supported Evonik's business. The stock rose 2.0% on the day. A friendlier competitive environment, though, is not the same as sustainably stronger demand, which leaves open how long that support lasts.

Portfolio changes are running in parallel. The sale of Oxeno is proceeding on schedule, with a buyer to be named in the coming months, while preparations have begun for a possible divestment of Syneqt. Evonik has not announced the completion of either transaction.

What to watch

For 2026, the group considers adjusted EBITDA in the upper half of its €2.0–2.2 billion range likely, with analysts on average already at the top end of that band — a demanding bar for any further re-rating. Free cash flow is expected at around €850 million this year, a yardstick for how much financial room the business generates during the restructuring. Good order books provide the momentum; converting them into earnings and cash is what will make the outlook hold.